Citius Pharmaceuticals shares jumped 22.12% after hours following the commercial launch of its LYMPHIR therapy and a fiscal 2025 business update.

The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We have processed the filings of the more than ...

The jump in price for CTXR stock comes alongside an increase in trading. As of this writing, more than 84 million shares of the stock have changed hands. For some context, the company’s daily average ...

Institutional Holdings information is filed by major institutions on form 13-F with the Securities and Exchange Commission. Major institutions are defined as firms or individuals that exercise ...

CTXR is trading near the bottom of its 52-week range and below its 200-day simple moving average. Price change The price of CTXR shares has decreased $0.02 since the market last closed. This is a 1.87 ...

Data is not available at this time. Insider Trading information for NDAQ is derived from Forms 3 and 4 filings filed with the U.S. Securities and Exchange Commission (SEC). Please Note:An FPI is ...

Citius Pharmaceuticals Inc (NASDAQ:CTXR) shares are trading lower by 14.2% to $3.75 during Wednesday’s session after the company announced a $3 million registered direct offering priced at-the-market ...

Citius Pharmaceuticals (NASDAQ:CTXR) stock is on the rise Friday despite a lack of news about the company today. The jump in price for CTXR stock comes alongside an increase in trading. As of this ...